Molecular Mechanisms of 6PPD and 6PPD-Q Toxicity in Neurodegenerative Diseases: A Network Toxicology and Experimental Validation Study.

Overview

1. Department of Physiology, School of Basic Medical Science, Central South University, Changsha 410011, China
2. Xiangya School of Medicine, Central South University, Changsha 410011, China
3. Nanjing Institute of Environmental Sciences, Ministry of Ecology and Environment, Nanjing 210042, China

Abstract

6PPD is a widely used tire antioxidant that readily transforms into its more toxic ozonation product, 6PPD-quinone (6PPD-Q). Both compounds are emerging environmental contaminants with potential neurotoxic risks, yet their molecular mechanisms in Alzheimer’s disease (AD) and Parkinson’s disease (PD) remain unclear. This study integrated network toxicology, molecular docking, transcriptomic validation, and experimental models to investigate their neurotoxic effects. In silico analyses predicted significant neurotoxicity and blood–brain barrier permeability for both compounds. Target prediction and PPI network analysis identified 145/121 overlapping targets with AD/PD for 6PPD and 120/100 for 6PPD-Q. Functional enrichment analysis suggested that 6PPD-associated targets were mainly enriched in axon regeneration-, p75NTR-, and AGE-RAGE-related pathways, whereas 6PPD-Q-associated targets were enriched in MAPK cascade-, endosomal TLR signaling-, and amyloid-β formation-related pathways. Molecular docking suggested favorable binding affinities between these compounds and several core targets, including MAP2K1, EGFR, GSK3B, and CYCS. Transcriptomic validation in GEO datasets prioritized multiple hub genes. In vivo experiments showed activation of apoptosis-related signaling in the brain, while in vitro assays demonstrated ROS accumulation and neuroinflammatory activation (elevated TNF-α, IL-1β, IL-6, IFN-γ). CYCS and MAP2K1 emerged as key convergent nodes. Our findings reveal distinct yet synergistic neurotoxic mechanisms of 6PPD and 6PPD-Q in AD and PD, highlighting tire-derived pollutants as potential environmental risk factors for neurodegenerative diseases.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data, not to its authors' code: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

• geo:GSE8397, at NCBI GEO; found in “Data Availability Statement”

Data Availability Statement

The data presented in this study are available upon request from the corresponding author. The transcriptomic datasets analyzed during the current study are available in the GEO repository, under accession numbers GSE8397 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8397) and GSE5281 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE5281).

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 6 keywords, 2 funders, 43 references.

Cite

This paper

Li, Z., Luo, Y., Wang, S., Xue, D., & Zhang, Y. (2026). Molecular Mechanisms of 6PPD and 6PPD-Q Toxicity in Neurodegenerative Diseases: A Network Toxicology and Experimental Validation Study. Toxics, 14(6), 504. https://doi.org/10.3390/toxics14060504

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/toxics14050443 [code]

6PPDQ Exposure Exacerbates Seizure-Induced Neuronal Damage via the TP53/Nrf2 Axis: An Integrated Strategy Combining Network Toxicology and Experimental Validation.

Journal: Toxics

In common: cellular / molecular, 4 references

[2] doi:10.1038/s41419-025-08391-5

TMBIM6 enhances dopaminergic neuron survival by modulating the IRE1a pathway in Parkinson's disease.

Journal: Cell death & disease

In common: NCBI GEO GSE8397, cellular / molecular

[3] doi:10.3390/biomedicines14050998 [code]

Integrative Multi-Omics and Machine Learning Analysis Identifies Therapeutic Targets and Drug Repurposing Candidates for Alzheimer's Disease.

Journal: Biomedicines

In common: cellular / molecular, 4 references

[4] doi:10.1038/s41467-026-74037-5

Microglial CD31 suppresses Aβ clearance and promotes Alzheimer pathology in 5×FAD mice.

Journal: Nature communications

In common: cellular / molecular, 2 references

[5] doi:10.1002/alz.71804

A meta-refined human Alzheimer's disease-associated gene subset shows partial mouse-model pathway correspondence and limited cross-cohort machine-learning transportability.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

In common: cellular / molecular, 2 references

[6] doi:10.3390/ijms27146196

Investigation of the Potential Neuroprotective Mechanisms of <i>Acalypha indica</i> Against Alzheimer's Disease by Integrated Bioinformatics Analysis.

Journal: International journal of molecular sciences

In common: cellular / molecular, 2 references

[7] doi:10.1038/s42003-026-10030-4 [code]

Cell-type-aware transcriptome-wide association studies identify 91 independent risk genes for Alzheimer's disease dementia.

Journal: Communications biology

In common: cellular / molecular, 2 references

[8] doi:10.1371/journal.ppat.1014314

Chemo-omic pipeline enables discovery of prion synaptotoxic pathways and inhibitory drugs.

Journal: PLoS pathogens

In common: other condition, cellular / molecular, 1 reference

[9] doi:10.1093/braincomms/fcag204 [code]

Altered rhythmic and arrhythmic electroencephalographic activity during non-rapid eye movement sleep in amnestic mild cognitive impairment.

Journal: Brain communications

In common: 2 references

[10] doi:10.1002/14651858.cd016297

Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease.

Journal: The Cochrane database of systematic reviews

In common: 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.